{"id":164863,"title":"NACI Rapid Response interim guidance on the use of Imvamune in the context of monkeypox outbreaks (mpox) in Canada, CCDR 48(7/8) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:19:44.434000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-rapid-response-interim-guidance-imvamune-monkeypox-outbreaks-canada.html?wbdisable=true","snippet":"NACI Rapid Response interim guidance on the use of Imvamune in the context of monkeypox outbreaks (mpox) in Canada, CCDR 48(7/8) - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du Canada Search Search Canada.ca Search Menu…","rawSnapshotUrl":"/api/snapshots/raw/164863","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141944/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-rapid-response-interim-guidance-imvamune-monkeypox-outbreaks-canada.html?wbdisable=true#ha_snapshot=164863","mimeType":"text/html","statusCode":200}